| Case Page

 | Case Page |

Case Page

 

Raptor Pharmaceutical Corp.

Case Summary

Raptor Pharmaceutical Corp. Securities Litigation

Case Summary

Case Status:    DISMISSED    
On or around 12/06/2016 (Court's order of dismissal)

Filing Date: October 05, 2016

According to a law firm press release, the Complaint alleges that on September 12, 2016, Raptor and Horizon Pharma Public Limited Company (“Horizon”) announced a definitive agreement and plan of merger pursuant to which Horizon will acquire each outstanding common share of Raptor for $9 per share in cash (the “Merger”). While the 50-day ($6.52) and 200-day ($5.19) moving averages for Raptor stock were below the $9/share transaction price prior to the Merger’s announcement, a closer look reveals that previously, shares of Raptor had consistently traded at or above the $9/share mark since 2013.

The Complaint alleges that the proposed Merger fails to reflect Raptor’s true value. Analyst expectations, historical trading prices, Raptor’s recent results, and an exciting pipeline of products that are either in the market already and/or coming soon to market demonstrate that the Merger undervalues the Company.

This case was voluntarily dismissed on December 2, 2016.

Company & Securities Information

Defendant: Raptor Pharmaceutical Corp.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: RPTP
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.

First Identified Complaint

Roman Lavrenov, et al. v. Raptor Pharmaceutical Corp., et al.

COURT: D. Delaware
DOCKET #: 16-CV-00901
JUDGE:
DATE FILED: 10/05/2016
CLASS PERIOD START: 09/12/2016
CLASS PERIOD END: 10/05/2016
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Brodsky & Smith, LLC
    Two Bala Plaza, Suite 602, Brodsky & Smith, LLC, PA 19004
    610.667.6200 610.667.6200 ·
  2. Rigrodsky & Long, P.A.
    919 N. Market Street, Suite 980, Rigrodsky & Long, P.A., DE 19803
    302.295.5310 302.295.5310 · info@rigrodskylong.com
First Identified Complaint (FIC) Filings:
No Document Title Filing Date
1 Class Action Complaint 10/05/2016
2 Stipulation Dismissing Actions as Moot and Retaining Jurisdiction to Determine Plaintiffs' Counsel's Application for an Award of Attorneys' Fees and Reimbursement of Expenses 12/05/2016
3 U.S. District Court Civil Docket 12/06/2016

Reference Complaint

—Reference Complaint Complaint Related Data is not available

Related District Court Filings

—Related District Court Filings Data is not available
 
 

Cases